Gilead’s stock has fallen 21% since April 30, underscoring investor questions about remdesivir’s potential – MarketWatch
Business News
- Gilead’s stock has fallen 21% since April 30, underscoring investor questions about remdesivir’s potential MarketWatch
- Gilead’s Veklury wins expanded FDA nod for moderate COVID-19 patients despite mixed data FiercePharma
- FDA grants EUA for Gilead’s remdesivir to treat Covid-19 Pharmaceutical Technology
- Gilead’s Veklury Gets FDA Nod for Expanded Use in Coronavirus Yahoo Finance
- FDA Expands Remdesivir Use for All COVID-19 Hospitalized Patients Medscape
- View Full Coverage on Google News
Source: Business News